结直肠癌术后辅助化疗序贯免疫治疗的临床观察

Abstract
Figure/Table
References
Related Citation (15)

［1］Gao P, Song YX, Wang ZN, et al. Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveillance, epidemiology, and end results (SEER) database\[J\]. BMC Cancer, 2013, 13:123.
［2］Lal N, Beggs AD, Willcox BE, et al. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy\[J\]. Oncoimmunology, 2015, 4(3): e976052.
［3］Correale P, Tagliaferri P, Fioravanti A, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colonystimulating factor and aldesleukin(GOLFIG1 Trial)\[J\]. Clin Cancer Res, 2008, 14(13):4192-4199.
［4］Sahu RP, Ocana JA, Harrison KA, et al. Chemotherapeutic agents subvert tumor immunity by generating agonists of plateletactivating factor\[J\]. Cancer Res, 2014, 74 (23):7069-7078.
［5］Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies\[J\]. Cancer Immunol Res, 2015, 3(5): 436-443.
［6］Correale P, Botta C, Rotundo MS, et al. Gemcitabine, oxaliplatin, levofolinate, 5fluorouracil, granulocytemacrophage colonystimulating factor, and interleukin2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG2 multicentric openlabel randomized phase Ⅲ trial\[J\]. J Immunother, 2014, 37(1):26-35.
［7］Correale P, Botta C, Martino EC, et al. Phase Ib study of polyepitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemoimmunotherapy for treatment of metastatic colorectal cancer patients\[J\]. Oncoimmunology, 2015, 5(4): e1101205.
［8］Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death\[J\]. Nat Rev Immunol, 2009, 9(5):353-363.
［9］Galon J, Costes A, SanchezCabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome\[J\]. Science, 2006, 313(5795): 1960-1964.
［10］王嘉，曲秀娟，张敬东，等. 肠癌患者外周血T淋巴细胞亚群数量及临床意义\[J\]. 中国医科大学学报, 2014, 43(4):289-292.
［11］Liao Y, Ou J, Deng J, et al. Clinical implications of the tumorinfiltrating lymphocyte subsets in colorectal cancer\[J\]. Med Oncol, 2013, 30(4):727.
［12］Evans CF , Galustian C, BodmanSmith M, et al. The effect of colorectal cancer upon host peripheral immune cell function\[J\]. Colorectal Dis, 2010, 12(6):561-569.
［13］BenitoMartin A, Di Giannatale A, Ceder S, et al. The new deal: a potential role for secreted vesicles in innate immunity and tumor progression\[J\]. Front Immunol, 2015, 6:66.
［14］Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity\[J\]. Front Immunol, 2014, 5:543.
［15］王辉. 肺癌患者外周血淋巴细胞免疫分型检测的临床意义\[J\]. 中外健康文摘，2014(22):97.
［16］Snook AE, Huang L, Schulz S, et al. Cytokine adjuvanation of therapeutic antitumor immunity targeted to cancer mucosa antigens\[J\]. Clin Transl Sci, 2008, 1(3):263-264.
［17］Gao D, Li C, Xie X, et al. (2014) Autologous tumor lysatepulsed dendritic cell immunotherapy with cytokineinduced killer cells improves survival in gastric and colorectal cancer patients\[J\]. PLoS One, 2014, 9(4): 1-9.
［18］Boyman O, Kovar M, Rubinstein MP, et al. Selective stimulation of T cell subsets with antibodycytokine immune complexes\[J\]. Science, 2006, 311(5769): 1924-1927.